Lead sponsor
Hanmi Pharmaceutical Company Limited
12 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
12
Trials led
3
Active
2,183
Total enrollment
120
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
4
Phase 2
5
Phase 3
3
Trials by status
Recruiting
1
Active, not recruiting
2
Completed
8
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusBMI ≥30Ph 3Active, not recruiting420
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesHbA1c 7-10%Ph 2Completed254
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in SubjectsBMI ≥18Ph 2Active, not recruiting215
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesHbA1c 7-10%Ph 2Completed209
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinBMI ≤45Ph 3Recruiting118
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusHbA1c 7-10%Ph 2Completed72
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDBMI ≥30Ph 1Completed66